ClinicalTrials.gg
RecruitingNCT07001800KATALYST-AVUpdated Jul 6, 2026

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

A Phase 2/3 interventional study of Ataciguat and Placebo in Moderate Aortic Valve Stenosis, sponsored by Kardigan, Inc.. Recruiting at 74 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Kardigan, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,276
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Aortic Valve Stenosis with a site in United States — 44 open to participants now, 68 under way, 3 of them phase 3. Aortic Valve Stenosis · United States.

Planned enrollment
15th of 125
1,276 · median 172
Started
2025
with 11 others
Phase 2/3
2 of 189
1 open now
Primary completion
2028-08
later than 51 of 67 live
Registered
175th of 189
by date

Among the 189 studies in Aortic Valve Stenosis with a site in United States, this one is the 15th largest by planned enrollment of the 125 interventional ones that give a count, is one of 12 that started in 2025, is one of 2 in phase 2/3, reaches primary completion later than 51 of the 67 other live ones, and was the 175th registered.

Aortic Valve Stenosis

1,026 studies on the registry are indexed under Aortic Valve Stenosis; 294 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

44 of the 189 studies in Aortic Valve Stenosis with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Aortic Valve Stenosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.

Read the detailed description

This study will be conducted in two parts: Part A and Part B. The purpose of Part A is to investigate whether ataciguat slows the progression of aortic valve calcium (AVC) deposition in adults with moderate calcific aortic valve stenosis (CAVS). The safety, tolerability, and pharmacokinetics of ataciguat will also be evaluated. Approximately 132 participants will be enrolled in Part A. Enrollment in Part B will begin once enrollment in Part A is complete. The purpose of Part B is to investigate whether ataciguat slows the rate of aortic valve area (AVA) loss and to evaluate the effect of ataciguat on peak oxygen consumption (VO2) in participants with moderate CAVS. The safety and tolerability of ataciguat will also be evaluated. Approximately 1144 participants will be enrolled in Part B.

03

Conditions studied

  • Moderate Aortic Valve Stenosis

Keywords

  • Ataciguat
  • sGC activator
  • sGC stimulator
  • Aortic valve stenosis
  • Moderate aortic valve stenosis
  • Calcific aortic valve stenosis
  • CAVS
  • Moderate Calcific Aortic Valve Stenosis
  • Aortic Stenosis (AS)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Adult male or female at least 50 years of age
  2. Has moderate CAVS as defined by:

    1. An AVA of ≥1.0 cm2 to ≤1.50 cm2
    2. An AVC score between >300 to 1200 Agatston units (AU) for women and between >300 to 2000 AU for men
  3. Has a (EF) of ≥45% at the time of Screening as determined by the echocardiography Imaging Core Laboratory
  4. For participants in CPET sub-study in Part A and all participants in Part B: If on beta blockade, the dose must be stable for at least 90 days prior to the Screening Visit with no anticipated changes during the study

Key Exclusion Criteria:

  1. For participants in the CPET sub-study in Part A and all participants in Part B: Has any medical or physical condition that, in the Investigator's opinion, could lead to an inability to complete Protocol-required CPET procedures (eg, pulmonary disease, joint, leg, hip, back conditions that limit physical activity, or other absolute for CPET)
  2. Anticipated or planned prior aortic valve replacement, repair, surgery, or intervention in the next 6 months
  3. Has moderate, moderate-to-severe, or severe (Grade 2 or higher) mitral stenosis, mitral regurgitation, and/or aortic regurgitation
  4. Has suspected or known congenital aortic valve disease including bicuspid aortic valve
  5. (NYHA) Class IV heart failure symptoms and/or requires continuous inotropes
  6. Has history of hypertrophic, genetic/familial cardiomyopathy or cardiomyopathy related to amyloid or sarcoid
  7. Has untreated obstructive coronary artery disease or anticipating coronary stenting surgery
  8. Abnormal (ECG) results or long-standing persistent or permanent atrial fibrillation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,276 participants (estimated)

Study arms

  • Experimental
    Ataciguat

    Drug: Ataciguat

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Ataciguat will be administrated daily for up to 156 weeks

  • DrugPlacebo

    Placebo will be administrated daily for up to 156 weeks

06

What researchers measure

Primary outcomes

  1. (Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24

    Time frame: Week 24

  2. (Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48

    Time frame: Week 48

  3. (Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48

    Time frame: Week 48

Secondary outcomes

  1. (Part A) Correlation in the change in AVC as assessed by non-contrast CT and change in VO2 at Week 48

    Time frame: Week 48

  2. (Part A) Change in VO2 from baseline to Week 48

    Time frame: Week 48

  3. Change in left ventricular diastolic function as assessed by E/e' from baseline to Week 48

    Time frame: Week 48

  4. (Part A) Change in Left Ventricular Mass Index (LVMI) from baseline to Week 48

    Time frame: Week 48

  5. (Part A) Change in Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) from baseline to Week 48

    KCCQ-23 is a patient reported outcome instrument with minimum score = 0 and maximum score = 100 where higher score indicates better health status. There are no units to the score.

    Time frame: Week 48

  6. (Part B) Change in AVC score as assessed by non-contrast CT from baseline to Week 48

    Time frame: Week 48

  7. (Part B) Time to decision to proceed with TAVR/SAVR or all-cause death

    Time frame: Week 158

  8. (Part B) Percentage of participants with progression to AVA <1.0cm2 at Week 48

    Time frame: Week 48

07

Study locations

49 of 74 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Aug 2028, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jun 3, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Sep 30, 2030
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07001800
Lead sponsor
Kardigan, Inc.
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Jun 27, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Jul 6, 2026

Study contacts

Kardigan Clinical Trial Information Team
Contact
clinicaltrials@kardigan.bio
1-877-310-5135

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ataciguat

Start the discussion